dalcetrapib

Phase 3Small molecule

Roche

dalcetrapib is one of 166 small molecule programs targeting Coronary Artery Disease. It is currently in Phase 3.

Indications

Total Trials

Active Trials

165

Competitors

Pipeline

Status by Indication[3][1]

Indication

Coronary Artery DiseaseActive, not recruiting

Cardiovascular DiseaseActive, not recruiting

Acute Coronary SyndromeActive, not recruiting

COVID-19Active, not recruiting

Heart DiseaseActive, not recruiting

Coronary Artery DiseasePhase 3

Active, not recruiting

Cardiovascular DiseasePhase 3

Active, not recruiting

Acute Coronary SyndromePhase 3

Active, not recruiting

COVID-19Phase 2

Active, not recruiting

Heart DiseasePhase 2

Active, not recruiting

Competition

Competitive Landscape

1931 competitors in COVID-19

#DrugCompanyPhaseTrials

dalcetrapib

Roche

Phase 3

1 2

Spikevax

Moderna

Preclinical

21 3

Bnt162b2

BioNTech

Preclinical

29 4

COVID-19 Vaccine

Moderna

Preclinical

27 5

Biaxin

AbbVie

Preclinical

2 6

Stivarga

Bayer

Preclinical

1 7

Aimovig

Amgen

Preclinical

1 8

Aldactone

Pfizer

Preclinical

1 9

Nexavar

Bayer

Preclinical

1 10

Singulair

AstraZeneca

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 3Recruiting

Acute Coronary Syndrome

NCT05918861

Clinical

Trials by Indication[1]

Heart Disease3 trials

A Study Assessing the Effect of RO4607381 on Vascular Function in Patients With Coronary Heart Disease (CHD) or CHD-Risk Equivalent Patients

Completed· Roche logo

Roche·Phase 2·NCT00655538·476 enrolled

A Study of the Effect of RO4607381 on Atherosclerotic Plaque in Patients With Coronary Heart Disease

Completed· Roche logo

Roche·Phase 2·NCT00655473·130 enrolled

A Study of RO4607381 in Patients With Coronary Heart Disease (CHD) or a CHD Risk Equivalent.

Completed· Roche logo

Roche·Phase 2·NCT00353522·135 enrolled

Acute Coronary Syndrome3 trials

A Study of Dalcetrapib in Patients Hospitalized For An Acute Coronary Syndrome (Dal-ACUTE)

Completed· Roche logo

Roche·Phase 3·NCT01323153·300 enrolled

A Study of RO4607381 in Stable Coronary Heart Disease Patients With Recent Acute Coronary Syndrome

Completed· Roche logo

Roche·Phase 3·NCT00658515·15,871 enrolled

Phase III, Double-blind, Randomized Placebo-controlled Study to Evaluate the Effects of Dalcetrapib on Cardiovascular (CV) Risk in a Genetically Defined Population With a Recent Acute Coronary Syndrome (ACS)

Recruiting·DDalCor Pharmaceuticals·Phase 3·NCT05918861·2,000 enrolled

Atorvastatin1 trial

A Formulation Screening Study of Dalcetrapib and Atorvastatin in Healthy Volunteers

Completed· Roche logo

Roche·Phase 1·NCT01363999·24 enrolled

Cholesterol1 trial

A Study to Assess the Effect of RO4607381 in Patients With Relatively Low Levels of High Density Lipoprotein-Cholesterol (HDL-C)

Completed· Roche logo

Roche·Phase 2·NCT00697203·292 enrolled

Safety and Efficacy1 trial

A Long Term Extension of Study NC19453 Evaluating Safety and Efficacy of RO4607381

Completed· Roche logo

Roche·Phase 2·NCT00400439·77 enrolled

5 more indications

Cardiovascular Disease1 trial

A Study of Dalcetrapib in Patients With Stable Coronary Heart Disease, With Coronary Heart Disease Risk Equivalents or at Elevated Risk for Cardiovascular Disease

Completed· Roche logo

Roche·Phase 3·NCT01516541·2,220 enrolled

COVID-191 trial

Effect of Dalcetrapib in Patients With Confirmed Mild to Moderate COVID-19

Completed·DDalCor Pharmaceuticals·Phase 2·NCT04676867·227 enrolled

Acute Lymphoblastic Leukemia1 trial

Effect of Dalcetrapib vs Placebo on CV Risk in a Genetically Defined Population With a Recent ACS

Completed·DDalCor Pharmaceuticals·Phase 3·NCT02525939·6,147 enrolled

Coronary Artery Disease1 trial

A Study of the Effect of Dalcetrapib on Artherosclerotic Disease in Patients With Coronary Artery Disease

Terminated· Roche logo

Roche·Phase 3·NCT01059682·936 enrolled

Unspecified1 trial

A Study of the Metabolic Profile of Dalcetrapib in Healthy Volunteers

Completed· Roche logo

Roche·Phase 1·NCT01476267·6 enrolled

Sources

References

[1]
ClinicalTrials.gov — 14 trial records for dalcetrapib. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — dalcetrapib compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for dalcetrapib. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Roche company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Roche

dalcetrapib

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Heart Disease3 trials

Acute Coronary Syndrome3 trials

Atorvastatin1 trial

Cholesterol1 trial

Safety and Efficacy1 trial

Cardiovascular Disease1 trial

COVID-191 trial

Acute Lymphoblastic Leukemia1 trial

Coronary Artery Disease1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News